Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies is under clinical development by Bristol-Myers Squibb and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies overview
Gene therapy is under development for the treatment of B cell malignancies including relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and B-cell lymphomas including non-Hodgkin lymphoma (iNHL), diffuse large b-cell lymphoma, transformed B-cell lymphoma, or high grade B-cell lymphoma, relapsed and refractory acute lymphocytic leukemia (ALL), chronic myelocytic leukemia (CML) and Burkitt Lymphoma. It is administered through intravenous route. The therapy comprises of autologous T-lymphocytes genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19 and armored with 4-1BBL (CD137L) transduced with retroviral vector. The therapy is developed based on the CAR (chimeric antigen receptor) and TCR (T cell receptors) technology platforms.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies’s drug-specific PTSR and LoA scores, buy the report here.